Healthcor Management LP Has Decreased Haemonetics (HAE) Position By $17.71 Million; 11 Analysts Bullish AbbVie Inc. (ABBV)

January 14, 2018 - By Michael Collier

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 70 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Monday, October 31 by Credit Suisse. Deutsche Bank maintained AbbVie Inc. (NYSE:ABBV) on Monday, July 17 with “Hold” rating. The firm earned “Hold” rating on Wednesday, October 11 by BMO Capital Markets. On Tuesday, August 11 the stock rating was upgraded by TheStreet to “Buy”. As per Thursday, September 8, the company rating was downgraded by JP Morgan. The firm has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. On Thursday, January 4 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Thursday, May 25 by Jefferies. Piper Jaffray maintained the shares of ABBV in report on Thursday, September 28 with “Buy” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Outperform” rating given on Wednesday, October 11 by Cowen & Co. See AbbVie Inc. (NYSE:ABBV) latest ratings:

04/01/2018 Broker: Jefferies Rating: Buy New Target: $120.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy New Target: $106.0 Maintain
20/11/2017 Broker: Cowen & Co Rating: Buy New Target: $105.0 Maintain
16/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $66 New Target: $84 Maintain
29/10/2017 Broker: SunTrust Rating: Buy New Target: $105.0 Maintain
30/10/2017 Broker: Leerink Swann Rating: Outperform Old Target: $108 New Target: $107 Maintain
16/10/2017 Broker: SunTrust Rating: Buy New Target: $95.0 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $66.0 Maintain
13/10/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $6.00 New Target: $9.00 Maintain
13/10/2017 Broker: UBS Rating: Neutral New Target: $9.00 Maintain

Healthcor Management Lp decreased Haemonetics Corp (HAE) stake by 21.7% reported in 2017Q3 SEC filing. Healthcor Management Lp sold 402,529 shares as Haemonetics Corp (HAE)’s stock rose 6.04%. The Healthcor Management Lp holds 1.45M shares with $65.17 million value, down from 1.85 million last quarter. Haemonetics Corp now has $3.39B valuation. The stock decreased 0.99% or $0.64 during the last trading session, reaching $64.12. About 869,054 shares traded or 85.27% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 45.56% since January 14, 2017 and is uptrending. It has outperformed by 28.86% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on February, 5. They expect $0.44 EPS, up 2.33% or $0.01 from last year’s $0.43 per share. HAE’s profit will be $23.24 million for 36.43 P/E if the $0.44 EPS becomes a reality. After $0.48 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.

Since August 10, 2017, it had 0 insider purchases, and 2 selling transactions for $1.46 million activity. Shares for $448,434 were sold by KROLL MARK W. MEELIA RICHARD J sold $1.01 million worth of stock.

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 25 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 5 by Benchmark. Jefferies maintained Haemonetics Corporation (NYSE:HAE) on Monday, January 8 with “Buy” rating. The stock has “Market Outperform” rating by JMP Securities on Thursday, July 13. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, October 6. The stock of Haemonetics Corporation (NYSE:HAE) earned “Market Perform” rating by Raymond James on Tuesday, January 2. The firm earned “Buy” rating on Thursday, December 21 by Jefferies. The firm has “Mkt Perform” rating given on Tuesday, February 7 by Barrington Research. The rating was upgraded by Goldman Sachs on Monday, May 16 to “Neutral”. The rating was upgraded by Barrington Research to “Outperform” on Tuesday, July 28. The firm earned “Outperform” rating on Tuesday, October 6 by Barrington Research.

Healthcor Management Lp increased Hill Rom Hldgs Inc (NYSE:HRC) stake by 459,770 shares to 584,770 valued at $43.27M in 2017Q3. It also upped Livanova Plc stake by 531,530 shares and now owns 931,530 shares. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was raised too.

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.42, from 1.7 in 2017Q2. It worsened, as 16 investors sold HAE shares while 60 reduced holdings. 33 funds opened positions while 64 raised stakes. 52.55 million shares or 2.13% less from 53.69 million shares in 2017Q2 were reported. Glenmede Na stated it has 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Amer Group Inc Inc has invested 0.01% in Haemonetics Corporation (NYSE:HAE). Parametric Port Assoc Ltd Co holds 0% or 84,875 shares. 19,498 are owned by Amg National Trust Bancorporation. Ls Advsrs Limited Liability Corp has 2,087 shares. Connor Clark Lunn Invest Limited holds 0% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 5,925 shares. Gotham Asset Management Lc accumulated 0.04% or 55,561 shares. Dimensional Fund Advsrs Lp stated it has 0.03% of its portfolio in Haemonetics Corporation (NYSE:HAE). Systematic Finance Management Limited Partnership invested in 0.03% or 35,360 shares. Vanguard Grp Incorporated owns 4.89M shares. Btim holds 0.21% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 294,791 shares. Principal Group Incorporated Incorporated has invested 0.02% in Haemonetics Corporation (NYSE:HAE). 27,000 were accumulated by Hutchin Hill Cap Lp. Moreover, Bessemer Grp Inc Inc has 0.01% invested in Haemonetics Corporation (NYSE:HAE) for 58,700 shares. Eaton Vance has 0% invested in Haemonetics Corporation (NYSE:HAE).

The stock increased 1.08% or $1.07 during the last trading session, reaching $100.34. About 4.37M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 14, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It dived, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Broderick Brian C has invested 0.86% in AbbVie Inc. (NYSE:ABBV). Signature Fin Mgmt Incorporated holds 0.16% or 6,848 shares. Grand Jean holds 0.36% or 11,165 shares. Shamrock Asset Mngmt Limited Liability Company reported 2,777 shares. Smith Moore & Com invested in 28,731 shares. Pinnacle Wealth Management Advisory Group Lc holds 11,287 shares. Silvercrest Asset Mngmt Gru Inc Limited Liability Corporation owns 0.19% invested in AbbVie Inc. (NYSE:ABBV) for 219,458 shares. Mitchell Mcleod Pugh And Williams reported 10,427 shares or 0.68% of all its holdings. Sequoia Fincl Advisors Llc owns 4,922 shares for 0.05% of their portfolio. Brown Advisory Inc holds 819,779 shares or 0.24% of its portfolio. Amer Economic Planning Incorporated Adv reported 0.08% of its portfolio in AbbVie Inc. (NYSE:ABBV). Ontario – Canada-based Omers Administration has invested 0.05% in AbbVie Inc. (NYSE:ABBV). Community Fincl Service Group Ltd Liability Co owns 2,600 shares. Cleararc Capital has 0.97% invested in AbbVie Inc. (NYSE:ABBV) for 72,980 shares. Campbell Newman Asset Management reported 25,548 shares or 0.41% of all its holdings.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $160.19 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 24.37 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.